Journal Article

ThiPhiSA: new pathways to TB prevention from community screening – a household-randomised controlled trial in KwaZulu-Natal, South Africa

Morton, Jennifer F, Lenn, Meena, Bosman, Shannon, Madonsela, Thandanani, Shapiro, Adrienne E, Reither, Klaus, Lynen, Lutgarde, Thomas, Katherine K, Essack, Zaynab, Misra, Shriya, Grabow, Cole, van Heerden, Alastair

2025

Overview

IntroductionTuberculosis (TB) remains the leading cause of infectious disease deaths, particularly among people living with HIV (PWH). Despite being preventable, TB preventive therapy (TPT) uptake is low in high-burden regions like South Africa, where new guidelines have expanded TPT eligibility and introduced shorter, more effective regimens like 3 months of weekly rifapentine and isoniazid (3HP). As differentiated service delivery models for HIV care have proven effective, there is increasing recognition that decentralising TPT delivery may improve coverage and completion. This study explores whether a community-based TPT delivery strategy can enhance uptake and completion of TPT compared with traditional clinic-based services.Method and analysisWe will conduct a household-randomised, non-blinded, controlled trial. Persons eligible for TPT will be recruited from the TB TRIAGE+Trial study, a community-based household TB screening study. Households containing at least one person eligible for TPT will be randomised 1:1 to either community-based TPT or standard-of-care clinic referral for TPT. At enrolment, all participants will be provided with a 2-week supply of TPT in the community. Participants randomised to the community arm will receive the entire course of TPT in a single dispense (12 weeks of 3HP or 6 months of isoniazid, if 3HP is contraindicated). Clinic-arm participants will be referred to their local clinic for the remainder of their course of TPT and will collect TPT refills on the clinic-determined schedule. Our primary outcome is the proportion of participants who complete a course of TPT. Secondary outcomes include overall adherence to TPT, predictors of adherence with TPT, participant satisfaction with the assigned TPT delivery method and adverse events.Ethics and disseminationThe study and its tools were approved by the Human Sciences Research Councils Research Ethics Committee (approval number: 2/25/10/23), based in Pretoria, Gauteng, South Africa, as well as the University of Washington Institutional Review Board (Study 00018448). Study findings will be shared through the community advisory group and local stakeholder meetings, relevant international and local meetings/conferences and peer-reviewed publications.Trial registration numberNCT06214910. Date and version: 3.0, 30 July 2024.

• Publisher: British Medical Journal Publishing Group,BMJ Publishing Group LTD,BMJ Publishing Group
• Subject: Adult / Antiretroviral drugs / Antitubercular Agents - administration & dosage / Antitubercular Agents - therapeutic use / Clinics / Community Health Services / Data collection / Drug dosages / Drug therapy / Family Characteristics / Female / HIV / HIV & AIDS / HIV Infections - complications / Households / Human immunodeficiency virus / Humans / Isoniazid - administration & dosage / Isoniazid - therapeutic use / Male / Mass Screening - methods / Patients / Prevention / Primary Prevention / Protocol / Public Health / Randomized Controlled Trials as Topic / Rifampin - administration & dosage / Rifampin - analogs & derivatives / Rifampin - therapeutic use / South Africa / Tuberculosis / Tuberculosis - diagnosis / Tuberculosis - prevention & control